Intravenous but not intragastric urogastrone-EGF is trophic to the intestine of parenterally fed rats

R A GOODLAD, T J G WILSON, W LENTON, H GREGORY, K G MCCULLAGH, AND N A WRIGHT

From the Cancer Research Campaign Cell Proliferation Unit, Department of Histopathology, Royal Postgraduate Medical School, Hammersmith Hospital, London, ICI, Alderley Park, Macclesfield, and G D Searle, High Wycombe, Bucks

SUMMARY The effects of β-urogastrone/human epidermal growth factor (URO-EGF) on intestinal epithelial cell proliferation were studied in rats in which intestinal cell proliferation had been reduced to a steady state basal level, by maintaining the rats on total parenteral nutrition. The accumulation of arrested metaphases over a two hour time period was determined in a dose response study. Increasing doses of URO-EGF progressively raised the two hour collection of metaphases and intestinal weights. Intravenous infusion of URO-EGF was also effective in restoring cell proliferation when it was infused after the intestine had become hypoproliferative. β-urogastrone/human epidermal growth factor administered through an intragastric cannulae thrice daily had no significant effect on intestinal weight or crypt cell production rate or metaphase collection. It is proposed that one of the in vivo actions of urogastrone-epidermal growth factor is the maintenance of gastrointestinal growth and that this occurs through a systemic rather than a luminal mechanism.

A physiological role for the polypeptide β-urogastrone-epidermal growth factor (URO-EGF) has yet to be established despite the considerable interest shown in the in vitro actions of URO-EGF. The location of the main sites of production of URO-EGF in the salivary glands and Brunners glands of the duodenum of man and the rat, however, might suggest that URO-EGF may have a role in the maintenance of gastrointestinal homeostasis.

β-urogastrone (human epidermal growth factor) is a natural human polypeptide which has similar chemical, physical, and physiological properties to rat and mouse EGF. While the growth promoting actions of URO-EGF in vitro are well characterised, its role in vivo is uncertain: in the foetus and newborn animal, URO-EGF stimulates the proliferation and differentiation of the epidermis, maturation of the pulmonary epithelium and accelerates the healing of corneal epithelium. β-urogastrone/human epidermal growth factor also stimulates the proliferation and maturation of the neonatal intestine, where it also increases the activity of intestinal ornithine decarboxylase, an enzyme associated with the initiation of cell proliferation. The presence of URO-EGF in a variety of body fluids, including saliva, plasma and milk, its production by the salivary and Brunners glands, the reports of a trophic action of saliva on the intestine, the demonstration of URO-EGF receptors in intestinal epithelial cells, and the reported cytoprotective effects on the duodenal mucosa all suggest that it has a role in the control of gastrointestinal homeostasis other than its ability to inhibit gastric acid secretion.

It has been reported that the injection of URO-EGF into rodents increases the incorporation of tritiated thymidine into DNA throughout the gastrointestinal tract, only in the stomach or only in starved animals. It has also been reported that URO-EGF stimulates gastrointestinal growth in...
undernourished young rats. A study of the short term effects of URO-EGF administration using the more robust stathmokinetic method, showed a trophic effect which was only observed in some of the intestinal sites studied and depended on the time after injection; however, this study used starved rodents which were not in a steady state of cell proliferation.

A more suitable model of the hypoplastic intestine exists in the rat maintained by isocaloric total parenteral nutrition (TPN), which is generally agreed to be the pertinent system for the study of effects of humoral factors on the intestine, as the intestine of the TPN rat is in a steady state, basal level of proliferation, with the direct and indirect effects of food (luminal nutrition) being abolished, and the effects of endogenous secretions considerably reduced.

We have used such a model to show that relatively low doses of URO-EGF, which should not alter acid secretion, can significantly increase intestinal epithelial cell proliferation in TPN rats. This model was used to further investigate the effects of recombinant URO-EGF on cell proliferation in the gastrointestinal tract. The first experiment reported in this paper investigated the effects of intravenous URO-EGF in a dose response study. The second experiment investigated the time course of the effects of URO-EGF when given after the intestine had atrophied (intervention). The effects of the intragastric administration of URO-EGF on crypt cell production rate and metaphase collection were also investigated.

**Methods**

**Animals**

Male 200 g Wistar rats (Olac Ltd, Blackthorn, Oxon, UK) were housed individually in wire bottomed Perspex cages. The rats had constant access to tap water and were subjected to a 14 hour light, 10 hour dark schedule. The rats were maintained on the respective treatments for 10 days, unless stated otherwise. Before the experiments the rats were maintained on a pelleted diet, Labshure PRD (Labshure Ltd, Poole, Dorset, UK).

**β-urogastrone/human epidermal growth factor**

The URO-EGF was recombinant polypeptide (supplied by ICI and G D Searle) derived from the expression of a synthetic gene in *E coli* and purified to >97% by tryptic digestion and purification as judged by amino acid analysis, HPLC in two systems and by acrylamide gel electrophoresis. It had the same amino acid sequence as natural human URO-EGF. The biological activity of the cloned URO-EGF was identical to that of natural URO-EGF purified from human urine in its ability to inhibit gastric acid secretion, its mitogenicity to cultured fibroblasts, its binding to EGF receptors, and it had identical radioimmunoassay standard curves to URO-EGF purified from human urine.

In the dose response study the rats were maintained by total parenteral nutrition (TPN), and URO-EGF was infused with the diet to give a daily intake of 0, 3, 15, 60 and 300 µg/rat/day (15 µg/rat/day was the dose used in our earlier study and all except the highest dose should be within the range quoted for rodent EGF). In the intragastric infusion studies URO-EGF was given at 800 h, 1600 h and 2400 h. The daily doses used were 15, 150, and 300 µg/rat/day.

**Jugular cannulation**

Rats were anaesthetised with 0-05 ml Hypnorm (0-315 mg/ml fentanyl citrate and 10 mg/ml fluanisone) (Janssen Pharmaceutica – Crown Chemicals Ltd, Lamberhurst, Kent, UK) im and 0-05 ml Valium (5 mg/ml diazepam – Roche Products, Welwyn Garden City, UK) by ip injection.

The right external jugular vein of the TPN rats was cannulated with a silastic catheter, filled with 1000 IU heparin-saline solution. The cannula was tied into the jugular vein with 6–0 black surgical silk and connected through a Harvard skin button and stainless steel tether (Harvard Apparatus Ltd, Fircroft Way, Kent, UK) to a Harvard miniature fluid swivel joint.

**Gastric intubation**

The gastric cannulae were made from 0-15 cm internal diameter 0-35 cm outside diameter silastic tubing (Esco Rubber Ltd, Teddington, UK). Two flanges approximately 0-3 cm apart were built up with silastic adhesive. The first flange was tied into the squamous stomach with a 3–0 purse string suture and the second flange was then pulled through a stab wound in the abdominal skin. The tubing was tunneled subcutaneously to exit in the neck, just caudal to the skin button, taped to the tether and
Urogastrone-EGF is trophic to TPN rats

protected with 5 mm plastic cable wrap (RS Components, London, UK).

INTRAVENOUS INFUSION
The swivel joint was clamped to the top of the Perspex cages, and was connected by vinyl tubing (Portex Ltd, Hythe, Essex, UK) to a multichannel peristaltic pump (Watson Marlow Ltd, Falmouth, Cornwall, UK).

The cannulae, silastic tubing and the swivel joints were sterilised by autoclaving. The other tubing, inlet manifold (made of plastic 3-way Luer fitting taps) and connectors were sterilised by pumping detergent hypochlorite solution through the assembled system, followed by a thorough rinse with sterile saline.

TPN DIET
The TPN diet was made up in sterile conditions in three litre infusion bags. The diet was kept in a fridge at 4°C and was pumped into the rats through vinyl tubing. One litre of the diet contained the following: 714 ml Vamin glucose, 92 ml Intralipid 20% (Kabivitrum Ltd, Riverside Way, Uxbridge), 140 ml dextrose 50%, 9 ml Vitilipid infant (Kabivitrum), 1 vial Solvito (Kabivitrum), 20 ml Addiphos (Kabivitrum), 12-8 ml 10% calcium gluconate, 3-4 ml 50% magnesium sulphate, and 8-7 ml 23-4% sodium chloride. Each rat was infused with 60 ml/day giving 1-8 g N, as purified amino acids, which is equivalent to 11-5 g of first class protein; 6-0 g lipid; 8-5 g glucose and 1047 kJ (250 kcal) per kg of rat per day.

Urine was tested regularly for protein, glucose, ketone, bilirubin, blood, urobilinogen, specific gravity and pH with Multistix-SG (Ames Reagent Strips, Miles Laboratories Ltd, Slough, UK) and no signs of metabolic imbalance were seen in any group of rats, except those on the highest intravenous dose of URO-EGF which looked sick and had traces of blood and glucose in their urine.

AUTOPSY PROCEDURE
The rats were given 1 mg/kg vincristine sulphate (Eli Lilly, Basingstoke, UK) intravenously, and killed by injection of 12 mg of pentobarbitone and exsanguination. The rats were weighed and the net weight of gut tissues determined. The stomach, small intestine, caecum and colon were removed, rinsed, blotted, and weighed. The stomach, caecum and samples of the small intestine and colon (as defined by their percentage length) were fixed in Carnoy’s fluid. All tissue weights were expressed as a percentage of the final body weight.

TWO HOUR METAPHASE COLLECTION
Rats were killed two hours after vincristine injection. Fixed tissue was stored in 70% v/v ethanol and later stained with the Feulgen reaction. The antral glands, intestinal crypts or colonic crypts were microdissected, the number of arrested metaphases in 10 crypts counted and the mean value per group calculated.

CRYPT CELL PRODUCTION RATE
Rats were killed at timed intervals after vincristine injection. The tissue was stained with the Feulgen reaction, the crypts microdissected and the number of arrested metaphases in 10 crypts counted; the mean number of metaphases per crypt was plotted against time and the slope of the line, fitted by least squares linear regression, gave the crypt cell production rate (CCPR).25

VILLUS AND CRYPT LENGTHS
These were measured in 5 μm paraffin embedded transverse sections stained with haematoxylin and eosin, using a calibrated eyepiece micrometer.34 Measurements were made in three animals per group.

STATISTICAL ANALYSIS
Crypt cell production rates and weights are shown ± standard errors. Differences between groups were tested by a two-sided Student’s t test for testing differences in either direction.

EXPERIMENTAL DESIGN
Intravenous urogastrone dose response study
The effects of 0 to 300 μg/rat/day of URO-EGF on the two hour collection of arrested metaphases were determined in a dose response study utilising parenterally maintained rats.

Intervention time course study
The aim of this study was to investigate whether URO-EGF could reverse the hypoplasia associated with TPN once it had become established and if so to investigate the time course of the response. Rats were maintained on TPN for four days, then given 60 μg/rat/day URO-EGF in their TPN diet and killed at six hour intervals. Proliferation was quantified by the two hour collection of arrested metaphases.

INTRAGASTRIC ADMINISTRATION OF UROGASTRONE
The effects of intragastric infusion of URO-EGF was investigated. A tube was placed in the squamous stomach of the rats at the time of their jugular cannulation. This tube was then used to infuse URO-EGF at eight hour intervals. The CCPR was measured after 10 days of daily dosing with URO-EGF at 15 μg/rat/day.
A further intragastric study was also carried out in which higher doses of URO-EGF (150 and 300 µg/rat/day) were used, incorporating the two hour metaphase arrest method.

Results

**Intravenous Urogastrone Dose Response Study**

There was a highly significant (p<0.001) correlation (r=0.997) between plasma URO-EGF and dose of URO-EGF administered. Plasma URO-EGF rose by 37.8 ± 1.2 pg/ml per µg administered per rat per day.

The effects of the various doses of URO-EGF administered intravenously on intestinal wet weights are shown in Figure 1. The dotted lines show the values in rats fed a pelleted diet ad lib in our previous study. The lowest dose of URO-EGF had little effect, but 15 µg/rat/day significantly increased the weights of the stomach, small intestine and colon. From 15–300 µg/rat/day there was a logarithmic relationship between dose and weight. The weights of the high dose group increased to values above those expected in orally fed rats, with the percentage increases in weight between the high dose and the control groups being 62%, 92%, 106%, and 208% for the stomach, small intestine, caecum, and colon respectively.

The two hour accumulation of metaphases in representative sites are shown in Figures 2a to d. There was no evidence of any effect at the lowest dose (3 µg/rat/day); however, there were significant increases with the 15 µg/rat/day group in all sites studied except the mid and distal colon. This increase in metaphase accumulation continued in a dose responsive manner in most sites. Whilst the number of metaphases in stomach and small intestine only
Urogastrone-EGF is trophic to TPN rats

just reached orally fed levels when given the highest dose of URO-EGF, the colonic values of the high dose group considerably exceeded the level seen in orally fed rats. The increase in the stomach value at the highest dose was 230%, the mean increase in metaphases in the five small intestinal sites was 101 ± 7.4% and the mean increase for the three colon sites was 427 ± 20%.

The rats in the 300 μg/rat/day group were in a poor condition. No obvious pathology was apparent, but the rat’s urine was bloody and glucose positive. The higher dose groups also had a reduced weight gain (Table 1) but the differences were not statistically significant.

The increase in metaphase collection was also reflected in the increase in measures of crypt and villus dimensions (Table 2), with 60 μg/rat/day of URO-EGF giving measures near those of orally fed rats.

INTERVENTION TIME COURSE STUDY

There was a general increase in tissue weights with time, and this was statistically significant (by analysis of variance) for the small intestine (p<0.05) and for the colon (p<0.01). The effects of URO-EGF on the accumulation of arrested metaphases is shown in Figure 3. There was a gradual increase in metaphases over the first 24 hours, becoming apparent 12 hours after the administration of URO-EGF in the stomach and small intestine; however there was no evidence of increased cell proliferation in the colon until 18 hours after the administration of URO-EGF. The rate of increase in arrested metaphases then levelled out after 24–50 hours. There was then an indication
of a further rise in arrested metaphases in the majority of sites studied.

**Intragastric Study**
The daily intragastric infusion of 15 μg of URO-EGF per rat had no effect on intestinal weight. The CCPR of the various intestinal sites is shown in Table 3 and although the CCPR appeared to be greater in the URO-EGF treated group, no significant differences were obtained. The increased CCPR (and variance) in the test group was caused by one animal which had raised levels of arrested metaphases; these were more than two standard deviations away from the arrest line of the other animals in most of the sites studied: the test and control groups were indistinguishable if the results from this animal were excluded.

Luminal administration of higher doses of URO-EGF also had no effect on either the weight of the intestine or the two hour metaphase accumulation (Table 4).

**Table 1** *Initial body weights, end weights and per cent weight increase (mean values ± SE)*

<table>
<thead>
<tr>
<th>Group</th>
<th>Start weight (g)</th>
<th>±</th>
<th>End weight (g)</th>
<th>±</th>
<th>Weight increase (%)</th>
<th>±</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intravenous urogastrone dose response experiment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control group</td>
<td>186-7</td>
<td>3-8</td>
<td>188-7</td>
<td>2-9</td>
<td>1-18</td>
<td>2-62</td>
</tr>
<tr>
<td>3 μg/rat/day URO-EGF</td>
<td>196-3</td>
<td>8-0</td>
<td>200-0</td>
<td>5-8</td>
<td>2-05</td>
<td>1-14</td>
</tr>
<tr>
<td>15 μg/rat/day URO-EGF</td>
<td>188-8</td>
<td>3-2</td>
<td>195-1</td>
<td>3-4</td>
<td>3-37</td>
<td>0-28</td>
</tr>
<tr>
<td>60 μg/rat/day URO-EGF</td>
<td>185-0</td>
<td>2-9</td>
<td>186-0</td>
<td>1-6</td>
<td>0-58</td>
<td>1-14</td>
</tr>
<tr>
<td>300 μg/rat/day URO-EGF</td>
<td>196-3</td>
<td>8-0</td>
<td>195-0</td>
<td>7-5</td>
<td>-0-58</td>
<td>1-38</td>
</tr>
<tr>
<td>Intervention (time course) study</td>
<td>201-8</td>
<td>1-7</td>
<td>208-0</td>
<td>2-2</td>
<td>3-09</td>
<td>0-75</td>
</tr>
<tr>
<td>Intragastric urogastrone crypt cell production rate experiment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TPN</td>
<td>212-9</td>
<td>3-8</td>
<td>196-6</td>
<td>2-8</td>
<td>-7-61</td>
<td>1-30</td>
</tr>
<tr>
<td>TPN + URO-EGF</td>
<td>215-7</td>
<td>4-2</td>
<td>204-3</td>
<td>2-6</td>
<td>-5-21</td>
<td>1-40</td>
</tr>
<tr>
<td>Intragastric urogastrone two hour metaphase collection experiment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TPN</td>
<td>215-8</td>
<td>6-3</td>
<td>206-0</td>
<td>4-0</td>
<td>-4-40</td>
<td>1-79</td>
</tr>
<tr>
<td>TPN + 150 μg/rat/day URO-EGF</td>
<td>207-0</td>
<td>3-0</td>
<td>211-4</td>
<td>4-4</td>
<td>2-19</td>
<td>2-36</td>
</tr>
<tr>
<td>TPN + 300 μg/rat/day URO-EGF</td>
<td>216-0</td>
<td>5-4</td>
<td>213-6</td>
<td>6-8</td>
<td>-1-00</td>
<td>3-00</td>
</tr>
</tbody>
</table>

**Table 2** *Effects of 60 μg/rat/day of urogastrone on the mean crypt and villus heights (μm)*

<table>
<thead>
<tr>
<th>Site</th>
<th>TPN control ±</th>
<th>Test ±</th>
</tr>
</thead>
<tbody>
<tr>
<td>75% of the length of the small intestine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Villus height</td>
<td>252-4</td>
<td>2-48</td>
</tr>
<tr>
<td>Crypt depth</td>
<td>200-1</td>
<td>2-49</td>
</tr>
<tr>
<td>50% of the length of the colon</td>
<td>199-0</td>
<td>1-79</td>
</tr>
</tbody>
</table>

* = p<0.01; † = p<0.001. The rats were maintained parenterally with or without URO-EGF for 10 days. Three animals per group were studied and the results are presented ±SE.

**Table 3** *Effects of 15 μg/rat/day of urogastrone administered intragastrically on the crypt cell production rates of the different sites in the gastrointestinal tract*

<table>
<thead>
<tr>
<th>Site</th>
<th>TPN controls ±</th>
<th>TPN + URO-EGF ±</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stomach</td>
<td>0-59</td>
<td>0-24</td>
</tr>
<tr>
<td>10% of the length of the small intestine</td>
<td>7-50</td>
<td>1-58</td>
</tr>
<tr>
<td>50% of the length of the small intestine</td>
<td>5-63</td>
<td>1-35</td>
</tr>
<tr>
<td>90% of the length of the small intestine</td>
<td>7-28</td>
<td>0-83</td>
</tr>
<tr>
<td>50% of the length of the colon</td>
<td>2-92</td>
<td>1-44</td>
</tr>
<tr>
<td>90% of the length of the colon</td>
<td>3-60</td>
<td>2-78</td>
</tr>
</tbody>
</table>

The rats were on their respective treatments for 10 days. The crypt cell production rate is expressed as cells produced per crypt per hour. There were seven animals per group.

**Table 4** *Effects of 150 μg/rat/day urogastrone and 300 μg/rat/day urogastrone on the two hour collection of metaphases*

<table>
<thead>
<tr>
<th>Site</th>
<th>TPN</th>
<th>TPN + 150 μg URO-EGF</th>
<th>TPN + 300 μg URO-EGF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stomach</td>
<td>1-13</td>
<td>0-06</td>
<td>2-74</td>
</tr>
<tr>
<td>10% of the length of the small intestine</td>
<td>24-7</td>
<td>2-4</td>
<td>27-2</td>
</tr>
<tr>
<td>50% of the length of the small intestine</td>
<td>24-0</td>
<td>3-9</td>
<td>20-5</td>
</tr>
<tr>
<td>90% of the length of the small intestine</td>
<td>23-9</td>
<td>1-9</td>
<td>23-3</td>
</tr>
<tr>
<td>50% of the length of the colon</td>
<td>15-1</td>
<td>3-83</td>
<td>7-3</td>
</tr>
<tr>
<td>90% of the length of the colon</td>
<td>13-8</td>
<td>3-88</td>
<td>5-8</td>
</tr>
</tbody>
</table>

The treatments lasted for 10 days. There were four animals in the control group, five in the 150 μg/rat/day group and four in the 300 μg rat/day group.
Urogastrone-EGF is trophic to TPN rats

Fig. 3  Two hour metaphase collection (mean value for 10 crypts or glands) at various times after the administration of urogastrone in the different sites along the gastrointestinal tract sampled. The rats were maintained by TPN for four days before the infusion of 60 µg/rat/day of urogastrone. Lines were fitted by eye. The dotted line shows the values obtained in orally fed rats.

Discussion

The results of the present study show that URO-EGF will stimulate intestinal epithelial cell proliferation and growth in TPN rats in all sites of the gastrointestinal tract in a dose dependent manner, with the most marked effects being observed in the stomach and colon. We have previously shown that a relatively low dose, which should not inhibit acid secretion, significantly increased crypt cell production throughout the intestine, with the CCPR's of the stomach and colon increasing to the levels observed in orally fed rats. The U-urogastrone/human epidermal growth factor was also effective in stimulating proliferation once hypoplasia had become established. The time course of events after this 'intervention' are described. The intragastric infusion of URO-EGF had no effect on intestinal weight or CCPR at the same dose that had significant effects throughout the intestine when
given intravenously, nor did it have any effect on intestinal weight or metaphase collection at higher doses.

Tissue wet weight is only a crude measure of intestinal hyperplasia, but when it is combined with increased metaphase collection can confirm that these increases in proliferation are linked to hyperplasia. We have also shown that these weight changes are accompanied by similar, significant changes in villus height and crypt depth (Table 2).

The intestinal atrophy associated with TPN should occur within a few days and the similarity between the two hour metaphase accumulations after four days of TPN in the intervention study and after 10 days TPN in the other studies, and the high degree of comparability between the various (TPN) control groups substantiates this; thus the TPN control rats should have been in a 'steady state' of reduced intestinal proliferation. The rats maintained on TPN showed a slight gain in body weight despite the surgery, loss of digesta and gut tissue. β-urolagastrene/human epidermal growth factor treated rats showed a greater weight gain which could be explained by the increase in gut weight. The rats dosed intragastrically all lost some weight but no significant differences between groups was noted.

The dose response studies showed that there was a log linear relationship between dose of URO-EGF and proliferation. The response of the different sites varied with the colon showing the most pronounced response increase. One could speculate that this reflects variations in receptor number among the cell populations.

The increase in proliferation in the intervention study was seen after 12 hours in the stomach and small intestine but only after 18 hours in the colon.

Similar differences in the time course of proliferative increase have been observed in the intestine of starved mice after refeeding, which implied that the delay in colonic response was the consequence of the greater time taken for digesta to reach the colon; however, the present results suggest that this delay reflects some inherent difference between the colon and the stomach-small intestine. The time taken for a proliferative response is a function of the cell cycle time of the tissue involved, thus the present result could be a reflection of the longer cycle time of the colonocyte.

The exact shape of time course curves is obscured by the variability of the data. The increase in proliferation in some intestinal sites appeared to tail off. The proliferation in other sites did not appear to do so, and in some of these sites proliferation seemed to be increasing again at the end of the investigation.

The intragastric infusion of various doses of URO-EGF had no significant effect on intestinal weights, CCPR or two hour metaphase collection. This is in conflict with the results of Dembinski et al who reported a trophic response of the stomach and duodenum when 30 μg/kg/day of URO-EGF was given intragastrically to rats. Although URO-EGF is taken up by the digestive tract in the neonate and weanling rat, recent evidence suggests that it is not absorbed in the adult gut. It has also been reported that intragastric URO-EGF has a cytoprotective action in the damaged gastric mucosa; however, the intestine was not damaged in this study. Another report suggests intragastric URO-EGF stimulates mucosal repair at doses that do not affect gastric acid secretion. This effect is observed within three to four hours after administration, which suggests that it may be caused by the stimulation of protective compounds, such as glucosaminoglycans and cell surface glycoproteins with subsequent alterations in cell membrane properties.

The mechanisms or significance of the in vivo trophic action of URO-EGF are as yet unknown. Gastrointestinal epithelial cells possess URO-EGF receptors and the lack of response to luminal URO-EGF would suggest that they are located on the baso-lateral side of the enterocyte. This action may either occur through a systemic mechanism or through the local release of URO-EGF from sites other than the salivary or Brunners glands. It is also possible that these actions are mediated by another hormone or factor. Several other humoral factors, especially enteroglucagon may also have a role to play in intestinal adaptation and their actions and interactions with URO-EGF have still as yet to be elucidated.

The trophic response of the gastrointestinal tract to URO-EGF could open up several avenues for the understanding of intestinal growth control and for the treatment of intestinal disease and dysfunction. The cytoprotective role of URO-EGF has already been advocated and the present results in the TPN rat would suggest that URO-EGF may be of use in the prevention or reversal of the atrophy associated with intravenous alimentation in the human. A human infant with a congenital malabsorption syndrome requiring intravenous alimentation has recently been treated with recombinant URO-EGF and intestinal proliferation increased significantly.

The present study has confirmed that TPN is associated with profound intestinal hypoplasia resulting in a new 'steady state'. We have also shown that URO-EGF was effective in reducing this hypoproliferative state when given either during the initiation of TPN associated hypoplasia (maintenance) or when hypoplasia had become established (intervention), suggesting that URO-EGF could play
an important role as a trophic factor in the maintenance of epithelial proliferation in the gastrointestinal tract.

We thank the Cancer Research Campaign for financial assistance. This study was presented in part at the British Society for Gastroenterology meeting in Liverpool 1984.

References

31 Smith J, Cook E, Fotheringham I, et al. Chemical
Goodlad, Wilson, Lenton, Gregory, McCullagh, and Wright

Intravenous but not intragastric urogastrone-EGF is trophic to the intestine of parenterally fed rats.

R A Goodlad, T J Wilson, W Lenton, H Gregory, K G McCullagh and N A Wright

_Gut_ 1987 28: 573-582
doi: 10.1136/gut.28.5.573

Updated information and services can be found at:
http://gut.bmj.com/content/28/5/573

_These include:_

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/